Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer

Oncologist

Volumn 16, Issue 9, 2011, Pages 1299-1306

  Pirl, William F ^a   Traeger, Lara ^a   Greer, Joseph A ^a   Bemis, Heather ^a   Gallagher, Emily ^a   Lennes, Inga ^a   Sequist, Lecia ^a   Heist, Rebecca ^a   Temel, Jennifer S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Depression; Epidermal growth factor receptor; Genotyping; Major depressive disorder; Non small cell

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BIOPSY; CANCER PATIENT; CANCER STAGING; CONSULTATION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EGFR GENE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MASS SCREENING; MOOD; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 80053215176     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0116     Document Type: Article

References (52)

1. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: A meta-analysis. Cancer 2009; 115:5349-5361.
2. Pinquart M, Duberstein PR. Depression and cancer mortality: A meta-analysis. Psychol Med 2010;40:1797-1810.
3. Thaker PH, Han LY, Kamat AA et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-944.
4. Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617-625.
5. Pirl WF, Temel JS, Billings A et al. Depression after diagnosis of advanced non-small cell lung cancer and survival: A pilot study. Psychosomatics 2008;49:218-224.
6. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
7. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
8. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
9. Lee YJ, Park IK, Park MS et al. Activating mutations within the EGFR ki-nase domain: A molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol 2009;135:1647-1654.
10. Wu M, Zhao J, Song SW et al. EGFR mutations are associated with prognosis but not with the response to first-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010;67: 343-347.
11. Aouizerat BE, Dodd M, Lee K et al. Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 2009;11:27-41.
12. Collado-Hidalgo A, Bower JE, Ganz PA et al. Cytokine gene polymorphisms and fatigue in breast cancer survivors: Early findings. Brain Behav Immun 2008;22:1197-1200.
13. Reyes-Gibby CC, Wu X, Spitz M et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol 2008;9:777-785.
14. Jatoi A, Qi Y, Kendall G et al. The cancer anorexia/weight loss syndrome: Exploring associations with single nucleotide polymorphism (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Support Care Cancer 2010;18:1299-1304.
15. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
16. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self report version of PRIME-MD: The PHQ primary care study. JAMA 1999; 282:1737-1744.
17. Ell K, Xie B, Quon B et al. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol 2008;26:4488-4496.
18. Fann JR, Berry DL, Wolpin S et al. Depression screening using the Patient Health Questionnaire-9 administeredonatouch screen computer. Psycoon-cology 2009;18:14-22.
19. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-613.
20. Löwe B, Schenkel I, Carney-Doebbeling C et al. Responsiveness of the PHQ-9 to psychopharmacological depression treatment. Psychosomatics 2006;47:62-67.
21. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
22. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
23. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649- 655.
24. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
25. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64:8919-8923.
26. Carlson LE, Angen M, Cullum J et al. High levels of untreated distress and fatigue in cancer patients. Br J Cancer 2004;90:2297-2304.
27. Kurtz ME, Kurtz JC, Stommel M, et al. Physical functioning and depression among older persons with cancer. Cancer Pract 2001;9:11-18.
28. LoConte NK, Else-Quest NM, Eickhoff J et al. Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer. Clin Lung Cancer 2008;9:171-178.
29. Cooley ME, Sarna L, Brown JK et al. Tobacco use in women with lung cancer. Ann Behav Med 2007;33:242-250.
30. Musselman DL, Miller AH, Porter MR et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: Preliminary findings. Am J Psychiatry 2001;158:1252-1257.
31. Lutgendorf SK, Lamkin DM, DeGeest K et al. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun 2008;22:890-900.
32. Knekt P, Raitasalo R, Heliövaara M et al. Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 1996;144:1096-1103.
33. Gross AL, Gallo JJ, Eaton WW. Depression and cancer risk: 24 years of follow-upof the Baltimore Epidemiologic Catchment Area sample. Cancer Causes Control 2010;21:191-199.
34. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-3837.
35. Rich TA. Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis. J Support Oncol 2007;5:167-174.
36. Gilbert J, Davis FC. Behavioral effects of systemic transforming growth factor-alpha in Syrian hamsters. Behav Brain Res 2009;198:440-448.
37. Rich T, Innominato PF, Boerner J et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:1757-1763.
38. Addison CL, Ding K, Zhao H et al. Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol 2010;28:5247-5256.
39. Vollebergh MA, Kappers I, Klomp HM et al. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomark-ers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:1939-1948.
40. Fukuyama T, Ichiki Y, Yamada S et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/ immunological responses both in vivo and in vitro. Cancer Sci 2007;98: 1048-1054.
41. Masago K, Fujita S, Hatachi Y et al. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor somatic mutation in patients with advanced non-squa-mous, non-small cell lung cancer. Cancer Sci 2008;99:2295-2301.
42. Volante M, Saviozzi S, Rapa I et al. Epidermal growth factor ligand/ receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer 2007;110:1321-1328.
43. Yonesaka K, Zejnullahu K, Lindeman N et al. Autocrine production of am-phiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008;14:6963-6973.
44. Raison CL, Miller AH. Depressionincancer: New developments regarding diagnosis and treatment. Biol Psychiatry 2003;54:283-294.
45. Elmquist JK, Scammell TE, Saper CB. Mechanisms of CNS response to systemic immune challenge: The febrile response. Trends Neurosci 1997; 12:565-570.
46. Dantzer R, Bluthé RM, Gheusi G et al. Molecular basis of sickness behavior. Ann N Y Acad Sci 1998;856:132-138.
47. Kent S, Bret-Dibat JL, Kelley KW et al. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci Biobehav Rev 1996;20: 171-175.
48. Passik SD, Dugan W, McDonald MV et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998;16:1594-1600.
49. Newell S, Sanson-Fisher RW, Girgis A et al. How well do medical oncologists' perceptions reflect their patients' reported physical and psychoso-cial problems? Data from a survey of five oncologists. Cancer 1998;83: 1640-1651.
50. Razavi D, Allilaire JF, Smith M et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996; 94:205-210.
51. Musselman DL, Somerset WI, Guo Y et al. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 2006;67:288-296.
52. Stockler MR, O'Connell R, Nowak AK et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: A placebo-controlled double-blind randomised trial. Lancet Oncol 2007;8:603-612.